Protalix BioTherapeutics, Inc. , today held an Analyst Event in which included the disclosure of new data regarding three new compounds in development, oral PRX-106 for immune mediated disorders, PRX-110 for Cystic Fibrosis , and PRX-107 for emphysema from heredity alpha1-antitrypsin deficiency.
More...
More...